article
P is for Psoriasis
5 December 2016 | By Niamh Louise Marriott, Digital Editor
P is for Psoriasis - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
List view / Grid view
Drug Markets
article
M is for MRSA
30 November 2016 | By Niamh Louise Marriott, Digital Editor
M is for MRSA - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
article
I is for Immuno-oncology
24 November 2016 | By Niamh Louise Marriott, Digital Content Producer
I is for Immuno-oncology - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in this cancer research...
news
ADHD market predicted to reach $13.9 billion by 2024
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…
news
Atrial fibrillation market will peak at $11.8 billion in 2022
2 August 2016 | By GlobalData
The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData...
news
Venous thromboembolism (VTE) therapeutics market set to hit $3.7 billion by 2025
1 August 2016 | By GlobalData
Growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says new report...
news
Companies prioritise competitive pricing in type 2 diabetes, says GlobalData
6 July 2016 | By Victoria White, Digital Content Producer
The type 2 diabetes market will see companies prioritisng competitive pricing in order to offset the impact of patent expiries, says GlobalData...
news
MenABCWY set to revolutionise the meningococcal vaccine market
29 June 2016 | By Victoria White, Digital Content Producer
GlobalData says MenABCWY has the potential to significantly change the approach used to prevent meningococcal disease...
news
Merck enters the IPF market through Afferent acquisition
27 June 2016 | By Victoria White, Digital Content Producer
Merck’s acquisition of Afferent Pharmaceuticals will provide it with an entry-platform into the fast-growing IPF market, according to GlobalData...
news
GlobalData on the difficulties and opportunities of Brexit for pharma
27 June 2016 | By Victoria White, Digital Content Producer
While a Brexit undoubtedly creates significant issues for the UK pharma industry, opportunities remain for the sector to thrive, according to GlobalData...
news
GlobalData discuss the consequences of the EU referendum
23 June 2016 | By Victoria White, Digital Content Producer
The company says for the healthcare industry to thrive in the event of the UK leaving the EU, the country would need to adopt a uniquely British approach...
news
Rheumatoid arthritis testing market to hit $399.5m by 2022
22 June 2016 | By Victoria White, Digital Content Producer
The rheumatoid arthritis testing market is forecast to rise from $338.5 million in 2015 to $399.5 million by 2022, according to GlobalData...
news
IPF market will grow to $3.2 billion by 2025, says GlobalData
21 June 2016 | By Victoria White, Digital Content Producer
The idiopathic pulmonary fibrosis (IPF) market will rise substantially from just over $900 million in 2015 to $3.2 billion by 2025, according to GlobalData...
news
Ganymed’s IMAB362 to bring hope to gastric cancer patients, says GlobalData
16 June 2016 | By Victoria White, Digital Content Producer
New data on IMAB362 provides hope for a subset of gastric and gastroesophageal junction adenocarcinoma patients, according to GlobalData...
news
Tecentriq to dominate the bladder cancer market, says GlobalData
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...
